Skip to main content
All
Stories
Press Releases
Documents
Events
Updates
Other
Press shift tab to select search category
Loading...
Newsroom
Investors
Careers
< Back
Careers
Careers
Working at Ipsen
Our Culture
All
Stories
Press Releases
Documents
Events
Updates
Other
Press shift tab to select search category
X
Loading...
Singapore
< Back
Global
EN
FR
Annual Report
EN
FR
Americas
Asia Pacific
Europe
Middle East & Africa
United States
Brazil
Canada
Mexico
Australia
China
Singapore
South Korea
Japan
Belgium
Ukraine
UK
Germany
France
Nordics
Greece
Italy
Netherlands
Spain
Poland
Russia
Czech Republic
Switzerland
Austria
UAE & Gulf
Saudi Arabia
Home
Company
< Back
Company
Company
History
Expertise
< Back
Expertise
Oncology
Rare Disease
Neuroscience
Science
< Back
Science
Pipeline
Clinical Trials
< Back
Clinical Trials
Find Clinical Trials
Products
< Back
Products
Cabometyx® (cabozantinib)
Diphereline® (triptorelin pamoate or acetate)
Dysport® (abobotulinumtoxinA)
Iqirvo® (elafibranor)
Somatuline® Autogel® (lanreotide acetate)
Post navigation
Previous
Next
Diphereline® (triptorelin pamoate or acetate)
Diphereline® (triptorelin pamoate or acetate)
-
31 October 2025
-
0 mins read
Post navigation
Previous
Next
Related Documents
Diphereline PR 3.75mg Package Insert
(492 KB)
Diphereline PR 11.25mg Package Insert
(425 KB)
X
You are now leaving Ipsen Singapore website. To continue, please click on
Continue
?
